Sign in
Taking people in SingaporePhase 2

Testing Less Frequent Dosing of Immunotherapy Drugs in Advanced Cancers

Compares longer gaps between immunotherapy doses with standard dosing in advanced cancers.

Key facts

Who runs it
National University Hospital, Singapore
Where
Singapore, SingaporeSee the site
Trial code
Registry title
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Status
Recruiting
Phase
Phase 2
People taking part
360 people, planned
Started
25 Nov 2024
Expected to end
31 Dec 2029
Type of study
Interventional, 6 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Extended Dosing Interval - A
  • Extended Dosing Interval - B
  • Extended Dosing Interval - C
  • Standard of Care - A
  • Standard of Care - B
  • Standard of Care - C
Record updated
10 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced stomach, gastro-oesophageal, oesophageal, liver or lung cancer who have not been treated before and are about to start an immunotherapy. It compares standard dosing with longer gaps between doses.

Age
21 to 99 years
Sex
All sexes can join.
Disease stage
Locally advanced or metastatic cancer that cannot be cured by surgery or radiotherapy. Cohort A: HER2-negative stomach, gastro-oesophageal junction or oesophageal adenocarcinoma. Cohort B: Child's A liver cancer (hepatocellular carcinoma). Cohort C: lung adenocarcinoma. Disease must be measurable (RECIST 1.1). ECOG 0-2.
Earlier treatment
No earlier treatment for the advanced cancer. Cohort A is about to start platinum double chemotherapy and nivolumab. Cohort B is about to start atezolizumab and bevacizumab. Cohort C is about to start pembrolizumab alone.
Biomarker or test result
Cohort A: PDL1 CPS ≥5%. Cohort C: PDL1 TPS ≥50%, EGFR/ALK wildtype.

Main reasons for not taking part

  • Earlier immune checkpoint inhibitor or investigational antibody treatment
  • Autoimmune disorders
  • Active infection including hepatitis B, hepatitis C or HIV
  • Unstable spinal cord compression or brain metastases
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Provision of informed consent prior to any study-specific procedure
  • Patients with one of the following:; Cohort A: Previously untreated locally advanced/metastatic HER2 -ve gastric/gastroesophageal junction/esophageal (PDL1 CPS ≥5% adenocarcinomas not amenable to curative surgery or radiotherapy who are above to begin platinum double and nivolumab; Cohort B: Previously untreated locally advanced/metastatic Child's A hepatocellular carcinoma not amenable to curative surgery or radiotherapy who are above to begin atezolizumab and bevacizumab; Cohort C: Previously untreated locally advanced/metastatic lung adenocarcinoma (PDL1 TPS≥50%, EGFR/ALK wildtype) not amenable to curative surgery or radiotherapy who are above to begin pembrolizumab monotherapy
  • Measurable disease per RECIST 1.1 criteria
  • ECOG Performance status is 0-2
  • Normal organ and bone marrow function measured within 28 days before the study as defined below:; Haemoglobin ≥ 8.0 g/dL and no blood transfusions in the 28 days prior to entry; Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L; No features suggestive of MDS/AML on peripheral blood smear; White blood cells (WBC) > 3x10\^9/L; Platelet count ≥ 100 x 10\^9/L; Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN; Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN)
  • A life expectancy ≥ 12 weeks in all patients
  • Females in childbearing age should be using adequate contraceptive measures, should not be breastfeeding and their pregnancy test prior to the start of treatment must be negative. Evidence of non-child-bearing potential is fulfilled by one of the following criteria at screening:
  • The post-menopausal period defined as age ≥50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
  • Women <50 years old they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range
  • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not a tubal ligatio
  • Male patients should be willing to use barrier contraception
  • The patient is willing to comply with the protocol during the study including undergoing treatment and scheduled visits and examinations including follow up
  • At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and is considered suitable for accurate repeated measurements

Who cannot take part

  • Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy
  • Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years
  • Unstable spinal cord compression/brain metastases unless asymptomatic and not requiring steroids for at least 2 weeks prior to the start of study treatment. For patients with brain metastases, gamma knife or stereotactic brain surgery is allowed prior to study treatment
  • Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. Minor surgery is allowed
  • Previous allogeneic bone marrow transplant
  • Severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which based on investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or having active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required
  • Autoimmune disorders
  • Males and females of reproductive potential who are not using an effective method of contraception and females who are pregnant or breastfeeding or have a positive serum pregnancy test prior to study entry
  • Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 99 years old?

Where in Singapore

  • Department of Hematology-Oncology, National University HospitaSingapore, SingaporeContact: Wei Peng YongTaking people

About the trial

What the trial wants to find out

This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in advanced/unresectable gastric/gastroesophageal junction/oesphageal adenocarcinomas with PDL1 CPS ≥5%, hepatocellular carcinoma andnon-small cell lung cancer with PDL1 TPS≥50% with no prior treatment. The investigators hypothesize that nivolumab, pembrolizumab and atezolizumab can be used efficiently at extended dosing intervals, compared to their approved labels with comparable clinical outcome.

The 6 groups in the trial

  • Cohort A (SOC)Existing treatment, for comparison

    Nivolumab, XELOX/FOLFOX

    Treatment: Standard of Care - A

  • Cohort A (EDI)Treatment being tested

    Nivolumab, XELOX/FOLFOX

    Treatment: Extended Dosing Interval - A

  • Cohort B (SOC)Existing treatment, for comparison

    Bevacizumab, Atezolizumab

    Treatment: Standard of Care - B

  • Cohort B (EDI)Treatment being tested

    Bevacizumab, Atezolizumab

    Treatment: Extended Dosing Interval - B

  • Cohort C (SOC)Existing treatment, for comparison

    Pembrolizumab

    Treatment: Standard of Care - C

  • Cohort C (EDI)Treatment being tested

    Pembrolizumab

    Treatment: Extended Dosing Interval - C

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers: Phase 2 Randomized Trial (VALUE-CHECK)
Plain-language title
Testing Less Frequent Dosing of Immunotherapy Drugs in Advanced CancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06422403, who can take part
Record updated
10 January 2025